CD25 is used as a biomarker to identify and quantify regulatory T-cells within the tumor microenvironment. High levels of CD25-expressing Tregs are often associated with poor prognosis in various cancers, including breast cancer, ovarian cancer, and melanoma. Measuring CD25 expression can provide valuable insights into the immune landscape of a tumor and help guide immunotherapeutic strategies.
